Sermorelin Pharmacokinetics (ADME)

What Sermorelin Is and Why Its Pharmacokinetics Matter

Sermorelin acetate is a truncated form of human growth hormone-releasing hormone, containing only the first 29 amino acids (GHRH 1-29) of the full 44-amino-acid native peptide. Those 29 residues retain full biological activity at the GHRH receptor 1. Understanding the ADME profile of sermorelin is not an academic exercise. It directly explains why the peptide is dosed at bedtime, why single daily injections can stimulate physiologic GH pulsatility, and why certain patient populations (especially those with hepatic or renal compromise) may handle the drug differently.

The FDA approved sermorelin as Geref Diagnostic (intravenous) in 1997 for evaluating pituitary GH reserve 2. The subcutaneous therapeutic formulation was later voluntarily withdrawn for commercial reasons, not safety signals. Today, prescribers access sermorelin through 503A compounding pharmacies under state and federal compounding law. Because the compound lacks a modern new drug application with full phase III PK data, much of what clinicians rely on comes from older studies, IV-route PK analyses, and extrapolation from the known enzymology of GHRH-class peptides 3.

Mechanism of Action: How Sermorelin Works at the Pituitary

Sermorelin binds the growth hormone-releasing hormone receptor (GHRH-R), a G-protein-coupled receptor expressed on somatotroph cells of the anterior pituitary. Receptor binding activates adenylate cyclase, raises intracellular cyclic AMP (cAMP), and opens voltage-gated calcium channels. The resulting calcium influx triggers exocytosis of stored GH granules 4.

This is a pulsatile signal, not a sustained one. That distinction matters. Continuous GHRH exposure downregulates the GHRH-R within hours, a phenomenon documented by Bilezikjian and Vale in rat pituitary cell cultures, where prolonged GHRH stimulation reduced subsequent GH secretory responses by over 50% 5. Sermorelin's short half-life (discussed below) is therefore a feature rather than a limitation. The peptide arrives, fires the somatotrophs, and clears before receptor desensitization takes hold. This preserves the hypothalamic-pituitary feedback architecture that exogenous recombinant GH injections bypass entirely.

A second effect occurs with repeated dosing over weeks. Chronic sermorelin administration appears to upregulate pituitary GH mRNA transcription, increasing the releasable GH pool. Gelato et al. reported that six months of nightly sermorelin injections (1 mcg/kg SC) raised mean 12-hour integrated GH concentrations by 67% from baseline in GH-deficient adults (N=10) 6.

Absorption After Subcutaneous Injection

The absorption of sermorelin from a subcutaneous depot is rapid but incomplete. After a standard SC dose of 0.2 to 0.3 mg, plasma sermorelin concentrations become detectable within 3 minutes and reach peak levels (Tmax) at approximately 5 to 20 minutes 7.

Absolute bioavailability by the SC route has never been published in a large formal crossover study. Estimates derived from comparing SC and IV area-under-the-curve (AUC) values in small PK analyses place it between 3% and 6%. That low figure is not surprising. The subcutaneous tissue is rich in DPP-IV and other aminopeptidases that begin degrading the peptide before it ever reaches systemic circulation 8. Injection-site factors (adipose thickness, local blood flow, temperature) introduce additional variability.

Despite this low systemic bioavailability, the SC route remains clinically effective because sermorelin's target, the anterior pituitary, is exquisitely sensitive. The threshold concentration required to trigger GH release from somatotrophs is in the low picomolar range. Even a small fraction of the injected dose reaching the pituitary portal circulation is sufficient to produce a meaningful GH pulse.

Injection timing also influences the pharmacodynamic outcome. Bedtime dosing synchronizes the exogenous GHRH pulse with the endogenous nocturnal GH surge that normally peaks during slow-wave sleep. Walker et al. demonstrated in a pediatric GHD cohort (N=20) that nightly SC sermorelin at 30 mcg/kg produced growth velocities of 7.0 cm/year over the first treatment year, compared to 4.0 cm/year during the pretreatment observation period 3.

Distribution: Where Sermorelin Goes in the Body

Published volume-of-distribution data for sermorelin in humans are limited. Based on its molecular weight (approximately 3,358 Da), high water solubility, and minimal protein binding, sermorelin distributes primarily within the extracellular fluid compartment. Peptides of this size typically exhibit a volume of distribution (Vd) of 0.1 to 0.3 L/kg, consistent with distribution limited largely to plasma and interstitial fluid 9.

Sermorelin does not cross the blood-brain barrier in pharmacologically relevant amounts. Its effects on the pituitary are mediated through the hypophyseal portal vasculature, where the blood-brain barrier is fenestrated. This anatomical detail is clinically relevant: sermorelin reaches its target organ (the anterior pituitary) without requiring CNS penetration, and it does not produce the central side effects sometimes associated with GH secretagogues that act through hypothalamic ghrelin receptors.

Plasma protein binding has not been formally characterized, but peptides in this molecular weight range and charge profile typically show minimal albumin binding (<20%). The practical implication is that hypoalbuminemic states (liver disease, nephrotic syndrome) are unlikely to alter free sermorelin concentrations to a clinically meaningful degree.

Metabolism: DPP-IV and the Enzymatic Fate of Sermorelin

Metabolism is the rate-limiting step in sermorelin clearance and the primary reason for its short duration of action. The dominant enzyme is dipeptidyl peptidase IV (DPP-IV, EC 3.4.14.5), a serine protease expressed on endothelial cells, hepatocytes, renal tubular epithelium, and circulating T lymphocytes 10.

DPP-IV cleaves the Tyr1-Ala2 dipeptide from the N-terminus of sermorelin, producing the inactive fragment GHRH(3-29). This cleavage is rapid. In vitro incubation of GHRH(1-44) with purified human serum DPP-IV showed greater than 50% degradation within 5 minutes at physiologic pH and temperature 10. The resulting GHRH(3-29) fragment has less than 1% of the GH-releasing potency of the intact peptide.

A second degradation pathway involves trypsin-like endopeptidases that cleave at basic residue pairs (Arg-Lys) within the mid-chain region. These enzymes contribute to clearance but are quantitatively secondary to DPP-IV 11.

The clinical significance of DPP-IV-mediated degradation extends to drug interactions. Patients taking DPP-IV inhibitors (sitagliptin, saxagliptin, linagliptin) for type 2 diabetes could theoretically experience delayed sermorelin clearance and prolonged GH-releasing activity. No formal interaction study has been published, but the mechanism is well-characterized. Dr. Michael Thorner of the University of Virginia, a pioneer in GHRH research, noted in a 1995 review: "The extremely short half-life of GHRH in plasma is predominantly due to dipeptidyl peptidase IV activity, and any intervention that inhibits this enzyme should be expected to prolong GHRH bioactivity" 12.

Hepatic metabolism plays a secondary role. The liver expresses DPP-IV on sinusoidal endothelium, and first-pass hepatic extraction contributes to clearance of peptide reaching the portal circulation. Severe hepatic impairment could theoretically reduce sermorelin clearance, though no dose-adjustment studies exist.

Elimination: Half-Life and Renal Clearance

Sermorelin's plasma elimination half-life is approximately 10 to 12 minutes following intravenous administration in healthy adults. This figure comes from early PK work by Frohman et al., who measured immunoreactive GHRH(1-44) disappearance after IV bolus and found a biexponential decay with an initial distribution phase (t½α ≈ 2 to 3 minutes) and a terminal elimination phase (t½β ≈ 10 to 12 minutes) 13.

After subcutaneous injection, the apparent half-life is modestly longer (estimated 15 to 20 minutes) because absorption from the SC depot continues as elimination proceeds, creating a "flip-flop" kinetic profile where the absorption rate, not the elimination rate, governs the terminal slope of the plasma concentration curve.

Elimination of sermorelin and its metabolites occurs primarily through renal filtration. The intact peptide (3,358 Da) and its DPP-IV-generated fragments are small enough to pass freely through the glomerular basement membrane. Renal peptidases in the proximal tubule further degrade filtered fragments into component amino acids, which are reabsorbed 14. The total renal clearance of immunoreactive GHRH has been estimated at 150 to 200 mL/min, approximating the glomerular filtration rate, which suggests minimal tubular reabsorption of the intact peptide 13.

In patients with significant renal impairment (GFR <30 mL/min), clearance of GHRH fragments may be delayed. Whether this produces clinically relevant prolongation of GH-releasing activity is unknown, as no dedicated renal impairment PK study has been conducted for sermorelin.

Pharmacokinetic-Pharmacodynamic Relationship

The relationship between sermorelin plasma levels and GH output is not linear. It follows a threshold model: once plasma sermorelin exceeds the minimum effective concentration at the pituitary (estimated in the range of 50 to 100 pg/mL), GH release is triggered. Higher plasma levels do not proportionally increase the GH response. This ceiling effect was demonstrated by Vance et al., who showed that doubling the IV GHRH dose from 1 mcg/kg to 3.3 mcg/kg increased peak GH by only 20%, not 230% 15.

This PK-PD disconnect has practical dosing implications. Escalating the sermorelin dose beyond 0.3 mg SC does not meaningfully increase GH output, but it does increase exposure to potential side effects (facial flushing, injection-site erythema). The Endocrine Society's 2011 clinical practice guideline on GH deficiency in adults notes that GHRH-based testing protocols use a standard dose of 1 mcg/kg IV, not weight-tiered escalation, precisely because the dose-response curve plateaus early 16.

The timing of measurement also matters for interpreting GH responses to sermorelin. Peak GH typically occurs 15 to 30 minutes after SC injection and returns to baseline within 60 to 90 minutes. A 2002 study by Aimaretti et al. confirmed that a combined GHRH-plus-arginine test produced peak GH at 30 minutes in 87% of subjects (N=316), establishing the standard sampling window still used in clinical practice 17.

Factors That Alter Sermorelin Pharmacokinetics

Several physiologic and pharmacologic variables modify sermorelin's ADME profile.

Age. Older adults show blunted GH responses to GHRH, partly due to reduced somatotroph mass and partly due to increased somatostatin tone. A study by Iranmanesh et al. (N=36) found that men over age 60 had 40% lower peak GH responses to IV GHRH(1-29) compared to men aged 20 to 35, despite equivalent plasma GHRH levels 18.

Body composition. Visceral adiposity increases circulating free fatty acids, which suppress GH secretion at the pituitary level. Patients with BMI >30 kg/m² typically show reduced peak GH after sermorelin, requiring clinicians to interpret stimulation-test results with BMI-specific cutoffs 16.

Concurrent somatostatin tone. Endogenous somatostatin opposes GHRH action at the pituitary. Fasting, sleep onset, and exercise reduce somatostatin tone, creating windows of enhanced sermorelin responsiveness. This is the pharmacologic rationale for bedtime dosing.

DPP-IV inhibitor co-administration. As noted above, drugs like sitagliptin (100 mg daily) inhibit >80% of plasma DPP-IV activity within 2 hours of dosing 19. In a patient taking a DPP-IV inhibitor, sermorelin clearance could be meaningfully delayed, though the clinical impact has not been studied directly.

Exogenous GH or IGF-1. Concurrent use of recombinant GH or IGF-1 increases hypothalamic somatostatin release through negative feedback, which could blunt the pituitary's response to sermorelin without altering sermorelin's own PK.

Clinical Implications of Sermorelin's PK Profile

The short half-life and pulsatile pharmacodynamics of sermorelin carry three practical messages for prescribers. First, single daily dosing is appropriate. There is no pharmacokinetic rationale for twice-daily injections. The peptide clears in under an hour, and the resulting GH pulse is self-limited by endogenous somatostatin feedback.

Second, sermorelin should be injected on an empty stomach. Food intake, particularly high-fat meals, acutely raises circulating free fatty acids and may blunt the GH response at the pituitary level, independent of any effect on peptide absorption 20.

Third, monitoring sermorelin plasma levels is not clinically useful. The peptide's half-life is too short, the assay too specialized, and the PK-PD relationship too nonlinear for plasma levels to guide dose titration. Instead, clinicians monitor downstream markers: serum IGF-1 at 4 to 6 week intervals, and, in some protocols, overnight GH sampling or provocative testing after a washout period. The 2011 Endocrine Society guideline recommends IGF-1 as the primary monitoring parameter for all GH-axis therapies, with a target in the age-adjusted upper half of the normal range 16.